Skip to content

Trigger point extracorporeal shock wave combined with ultrasound-guided steroid injection for Idiopathic Frozen Shoulder:A prospective single-blind randomized controlled study

Trigger point extracorporeal shock wave combined with ultrasound-guided steroid injection for Idiopathic Frozen Shoulder:A prospective single-blind randomized controlled study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082994
Enrollment
Unknown
Registered
2024-04-12
Start date
2024-04-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Frozen Shoulder

Interventions

Combined treatment group:The patient underwent extracorporeal shock wave therapy at the trigger point first, and then underwent ultrasound-guided steroid injection therapy around the shoulder 2 hours
Pure shock wave therapy group:The patient only underwent extracorporeal shock wave therapy for trigger points. Treatment was given twice a week with a 2-day interval, and lasted for 2 weeks.
Pure shoulder injection group:The patient was simply treated with ultrasound-guided steroid injection around the shoulder, once a week for two consecutive weeks.

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for primary frozen shoulder;2.Age between 40 and 60 years old;3.Patients with a visual analog scale (VAS score) of =5 points;4.Patients in the first or second stage of IFS;5.Loss of ROM in at least two directions by 25%;6.Symptoms of shoulder pain and movement disorder lasting for more than 3 months, without taking analgesic drugs other than non-steroidal analgesics

Exclusion criteria

Exclusion criteria: 1.Patients allergic to drugs related to this test or with contraindications for shock wave therapy; 2. Patients who have previously undergone periarthritis of the shoulder injection therapy or surgical treatment of the shoulder joint; 3. Patients with other factors causing sleep disorders in addition to shoulder pain; 4. Patients with diabetes and HbA1c = 7.0%; 5. Concomitant pregnancy, local or systemic infection, severe cardiovascular and cerebrovascular disease, liver and kidney dysfunction.

Design outcomes

Secondary

MeasureTime frame
Shoulder joint active range of motion;Constant-Murley;Athens insomnia scale;

Primary

MeasureTime frame
Visual Analogue Scale;

Countries

China

Contacts

Public ContactYan Yuan

Affiliated Hospital of Xuzhou Medical University

1046112@qq.com+86 180 5226 8635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026